BOEDDINGHAUS, Jasper, Thomas NESTELBERGER, Patrick BADERTSCHER, Raphael TWERENBOLD, Brigitte FITZE, Desiree WUSSLER, Ivo STREBEL, Maria Rubini GIMENEZ, Karin WILDI, Christian PUELACHER, Jeanne du Fay DE LAVALLAZ, Loris OEHEN, Joan WALTER, Oscar MIRO, Javier F. MARTIN-SANCHEZ, Beata MORAWIEC, Eliska POTLUKOVA, Dagmar I. KELLER, Tobias REICHLIN, Christian MUELLER, Zaid SABTI, Michael FREESE, Claudia STELZIG, Samyut SHRESTHA, Nicolas SCHAERLI, Nikola KOZHUHAROV, Dayana FLORES, Jens LOHRMANN, Ewalina BISKUP, Wanda KLOOS, Stefan OSSWALD, Deborah MUELLER, Lorraine SAZGARY, Beatriz LOPEZ, Esther Rodriguez ADRADA, Damian KAWECKI, Piotr MUZYK, Ewa NOWALANY-KOZIELSKA, Jiří PAŘENICA, Eva GANOVSKÁ, Kathrin MEISSNER, Caroline KULANGARA, Riham MAHFOUZ, Beate HARTMANN, Ina FEREL, Isabel CAMPODARVE, Katharina RENTSCH, Arnold VON ECKARDSTEIN, Andreas BUSER and Nicolas GEIGY. Predicting Acute Myocardial Infarction with a Single Blood Draw. Clinical Chemistry. Washington, USA: Amer. Assoc. Clinical Chemistry, 2019, vol. 65, No 3, p. 437-450. ISSN 0009-9147. Available from: https://dx.doi.org/10.1373/clinchem.2018.294124.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Predicting Acute Myocardial Infarction with a Single Blood Draw
Authors BOEDDINGHAUS, Jasper (756 Switzerland), Thomas NESTELBERGER (756 Switzerland), Patrick BADERTSCHER (756 Switzerland), Raphael TWERENBOLD (756 Switzerland), Brigitte FITZE (756 Switzerland), Desiree WUSSLER (756 Switzerland), Ivo STREBEL (756 Switzerland), Maria Rubini GIMENEZ (756 Switzerland), Karin WILDI (756 Switzerland), Christian PUELACHER (756 Switzerland), Jeanne du Fay DE LAVALLAZ, Loris OEHEN (756 Switzerland), Joan WALTER (756 Switzerland), Oscar MIRO (724 Spain), Javier F. MARTIN-SANCHEZ (724 Spain), Beata MORAWIEC (616 Poland), Eliska POTLUKOVA (756 Switzerland), Dagmar I. KELLER (756 Switzerland), Tobias REICHLIN (756 Switzerland), Christian MUELLER (guarantor), Zaid SABTI (756 Switzerland), Michael FREESE (756 Switzerland), Claudia STELZIG (756 Switzerland), Samyut SHRESTHA (756 Switzerland), Nicolas SCHAERLI (756 Switzerland), Nikola KOZHUHAROV (756 Switzerland), Dayana FLORES (756 Switzerland), Jens LOHRMANN (756 Switzerland), Ewalina BISKUP (756 Switzerland), Wanda KLOOS (756 Switzerland), Stefan OSSWALD (756 Switzerland), Deborah MUELLER (756 Switzerland), Lorraine SAZGARY (756 Switzerland), Beatriz LOPEZ (724 Spain), Esther Rodriguez ADRADA (724 Spain), Damian KAWECKI (616 Poland), Piotr MUZYK (616 Poland), Ewa NOWALANY-KOZIELSKA (616 Poland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Eva GANOVSKÁ (703 Slovakia, belonging to the institution), Kathrin MEISSNER (756 Switzerland), Caroline KULANGARA (756 Switzerland), Riham MAHFOUZ (756 Switzerland), Beate HARTMANN (756 Switzerland), Ina FEREL (756 Switzerland), Isabel CAMPODARVE (724 Spain), Katharina RENTSCH (756 Switzerland), Arnold VON ECKARDSTEIN (756 Switzerland), Andreas BUSER (756 Switzerland) and Nicolas GEIGY (756 Switzerland).
Edition Clinical Chemistry, Washington, USA, Amer. Assoc. Clinical Chemistry, 2019, 0009-9147.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.292
RIV identification code RIV/00216224:14110/19:00111299
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1373/clinchem.2018.294124
UT WoS 000459957500013
Keywords in English SENSITIVITY CARDIAC TROPONIN; CHEST-PAIN SYMPTOMS; HOUR RULE-IN; EARLY-DIAGNOSIS; 2-HOUR ALGORITHM; RELATIVE CHANGES; RAPID RULE; VALIDATION; ABSOLUTE; BIOMARKER
Tags 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/1/2020 14:47.
Abstract
BACKGROUND: We desired to determine cardiac troponin (cTn) concentrations necessary to achieve a positive predictive value (PPV) of >75% for acute myocardial infarction (AMI) to justify immediate admission of patients to a monitored unit and, in general, early coronary angiography. METHODS: In a prospective multicenter diagnostic study enrolling patients presenting to the emergency department with symptoms suggestive of AMI, final diagnoses were adjudicated by 2 independent cardiologists based on clinical information including cardiac imaging. cTn concentrations were measured using 5 different sensitive and high-sensitivity cTn (hs-cTn) assays in a blinded fashion at presentation and serially thereafter. The diagnostic end point was PPV for rule-in of AMI of initial cTn concentrations alone and in combination with early changes. RESULTS: Among 3828 patients, 616 (16%) had an AMI. At presentation, 7% to 14% of patients had cTnT/I concentrations associated with a PPV of >= 75%. Adding absolute or relative changes did not significantly further increase the PPV. PPVs increased from 46.5% (95% CI, 43.6-49.4) for hs-cTnT at presentation >14 ng/L to 78.9% (95% CI, 74.7-82.5) for >52 ng/L (P < 0.001), whereas PPVs in higher hs-cTnT strata remained largely unchanged [e.g., 82.4% (95% CI, 77.5-86.7) for >80 ng/L vs 83.9% (95% CI, 76.0-90.1) for >200 ng/L (P = 0.72)]. The addition of early changes in hs-cTnT further increased the PPV up to 60 ng/L, but not for higher concentrations. CONCLUSIONS: Serial sampling does not seem necessary for predicting AMI and concurrent decision-making in about 10% of patients, as it only marginally increases the PPV for AMI and not in a statistically or clinically significant way. (c) 2018 American Association for Clinical Chemistry
PrintDisplayed: 22/7/2024 20:33